Printer Friendly

IVAX ANNOUNCES RESULTS OF ANNUAL MEETING AND PROMOTION OF DR. JOHN K. WHISNANT

 MIAMI, July 23 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced the results of its annual meeting of stockholders held today. The stockholders elected the following 15 persons to the board of directors to serve until the next annual meeting of stockholders: Phillip Frost, M.D.; Isaac Kaye; Jack Fishman, Ph.D.; Charles Hsiao, Ph.D.; Jospeh Giegel, Ph.D.; Mark Andrews; Francesco Bellini, Ph.D.; Ernst Biekert, Ph.D.; Dante B. Fascell; Harold S. Geneen; Lyle Kasprick; Harvey M. Krueger; John H. Moxley III, M.D.; M. Lee Pearce, M.D.; and Michael Weintraub. All of such persons were incumbent directors. The stockholders also approved a proposal to amend IVAX' stock option plan to increase the number of shares available for issuance under the plan by 3 million shares to 11.5 million shares and a proposal to change IVAX' state of incorporation from Delaware to Florida. IVAX intends to effectuate the reincorporation on July 30, 1993.
 IVAX also announced that Dr. John K. Whisnant, the vice president of Research and Development of Baker Norton Pharmaceuticals, Inc., was promoted to the position of senior vice president of Research and Development. Dr. Whisnant has been in charge of Baker Norton Pharmaceuticals' research and development efforts since joining the company in July 1992. Prior to joining Baker Norton Pharmaceuticals, Dr. Whisnant was vice president and medical director of Fujisawa Pharmaceutical Company U.S.A.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of generic pharmaceuticals in the United Kingdom, Ireland and other countries; H N Norton Co, a manufacturer of generic pharmaceuticals in the United States; Goldline Laboratories, Inc., a national marketer of generic prescription and over the counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Baker Cummins, Inc., a marketer of brand name pharmaceuticals in Canada; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 7/23/93
 /CONTACT: Richard C. Pfenniger Jr., senior vice president-legal affairs of IVAX Corporation, 305-590-2309/
 (IVX)


CO: IVAX Corporation ST: Florida IN: MTC SU: PER

JB-AW -- FL001 -- 5093 07/23/93 11:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1993
Words:414
Previous Article:WOLOHAN LUMBER CO. DECLARES QUARTERLY DIVIDEND
Next Article:IVAX ANNOUNCES RECORD REVENUES AND PRE-TAX EARNINGS
Topics:


Related Articles
IVAX ACQUIRES DVM PHARMACEUTICALS, INC.
IVAX JOINS FORTUNE 500; EXPANDS MANAGEMENT TEAM
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX CORPORATION APPOINTS DR. SAMUEL BRODER AS CHIEF SCIENTIFIC OFFICER
IVAX Corporation Appoints Robert C. Strauss as President and Chief Operating Officer
Preclinical Studies Conducted With NIH Indicate IVAX' Elmiron(R) Holds Promise As a Treatment for Progressive Kidney Disease and Atherosclerosis
IVAX Announces 1997 Second Quarter Financial Results and Resignation of Company President Robert Strauss
Dr. Rafick G. Henein Named President and CEO Of IVAX Subsidiary Zenith Goldline Pharmaceuticals
IVAX Announces Management Change.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters